Bifogade filer
Kurs
+6,02%
Likviditet
2,53 MSEK
Kalender
Tid* | ||
2025-02-25 | 08:30 | Bokslutskommuniké 2024 |
2024-11-27 | - | Kvartalsrapport 2024-Q3 |
2024-08-05 | - | Kvartalsrapport 2024-Q2 |
2024-06-19 | - | Årsstämma |
2024-04-29 | - | Kvartalsrapport 2024-Q1 |
2024-04-26 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2024-02-21 | - | Bokslutskommuniké 2023 |
2023-11-21 | - | Extra Bolagsstämma 2023 |
2023-11-09 | - | Kvartalsrapport 2023-Q3 |
2023-08-30 | - | Kvartalsrapport 2023-Q2 |
2023-05-29 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2023-05-26 | - | Årsstämma |
2023-05-23 | - | Kvartalsrapport 2023-Q1 |
2023-03-16 | - | Extra Bolagsstämma 2022 |
2023-02-23 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-04-08 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2022-04-07 | - | Årsstämma |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-07 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2021-05-06 | - | Årsstämma |
2021-04-28 | - | Kvartalsrapport 2021-Q1 |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-09-23 | - | Extra Bolagsstämma 2020 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-08 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2020-05-07 | - | Årsstämma |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Kvartalsrapport 2019-Q3 |
2019-08-23 | - | Kvartalsrapport 2019-Q2 |
2019-04-29 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2019-04-26 | - | Årsstämma |
2019-04-24 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-07 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2018-05-03 | - | Årsstämma |
2018-04-27 | - | Kvartalsrapport 2018-Q1 |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-11-10 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-04-26 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2017-04-25 | - | Årsstämma |
2017-04-20 | - | Kvartalsrapport 2017-Q1 |
2017-02-15 | - | Bokslutskommuniké 2016 |
2016-12-09 | - | Extra Bolagsstämma 2016 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-05-31 | - | X-dag ordinarie utdelning IMMNOV 0.00 SEK |
2016-05-30 | - | Årsstämma |
2016-02-24 | - | Bokslutskommuniké 2015 |
2015-09-28 | - | Extra Bolagsstämma 2015 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will present at the Redeye Technology & Life Science Day on December 3, hosted by Redeye.
Redeye Technology & Life Science Day gathers over 40 leading Nordic companies for a live-streamed event to showcase the groundbreaking work of these companies. During the event, Immunovia CEO Jeff Borcherding will be present in Stockholm to share the company's latest developments.
Event attendees are encouraged to take the opportunity to meet with Jeff and Immunovia's CFO, Karin Almqvist-Liwendahl. Investors can also view the broadcast online at: https://www.redeye.se/events/1038747/redeye-technology-life-science-day
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist-Liwendahl
CFO
karin.almqvist.liwendahl@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com